What are the key cardiac safety considerations with anthracyclines like doxorubicin?

• A. Cardiotoxicity risk increases with cumulative dose; monitor cardiac function (e.g., echocardiography); consider dexrazoxane for high‑risk exposure; watch for signs of heart failure.
• B. Cardiac toxicity is rare and not dose‑related; no routine cardiac monitoring is needed.
• C. Dexrazoxane should never be used with anthracyclines due to adverse interactions.
• D. Cardiac toxicity only occurs if concurrent chest radiation is given.

Answer: (A)

Anthracycline cardiotoxicity is dose-related and cumulative. Each dose adds to the total lifetime exposure, and the risk of developing cardiomyopathy or heart failure increases as that cumulative dose rises. Because damage can develop insidiously, baseline and periodic cardiac assessments—typically with echocardiography to measure left ventricular function—are important during and after therapy to catch early decline.

Dexrazoxane can be used as a cardioprotectant for patients expected to receive high cumulative doses, helping to reduce the risk of cardiac injury. Its use is balanced against cancer treatment goals and patient factors, but it is not indication that cardiotoxicity cannot occur with anthracyclines; rather, it provides a strategy to mitigate risk in high-exposure scenarios.

Be vigilant for signs of heart failure—shortness of breath, fatigue, edema, reduced exercise tolerance—and manage promptly with appropriate heart failure care.

The other statements don’t fit because cardiac toxicity from anthracyclines is not rare or non–dose-related, dexrazoxane is not categorically contraindicated, and toxicity can occur without chest radiation ( radiation raises risk but is not required for toxicity).